Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Smarter science,
safer pets.
Smarter science,
safer pets.
We strive to create a world where no pet has to suffer needlessly from conditions we have the power to treat — delivering high-tech care that leads to safer, healthier, and happier lives.
We strive to create a world where no pet has to suffer needlessly from conditions we have the power to treat — delivering high-tech care that leads to safer, healthier, and happier lives.
What We Do
We are developing biological therapies based on antibodies to transform veterinary care.
By combining innovation and compassion, we aim to develop advanced treatments more accessible, generating real change for pets and their families.
We are building biological therapies based on antibodies to transform veterinary care. By combining innovation and compassion, we aim to make advanced treatments more accessible, generating real change for pets and their families.
Antibodies
Multi-Product Platform
Animal Health
Biological Therapies
Pet Care
Ai
Biotech
Pharmaceutical
Targeted Therapies
Innovation
Our Science
The Rigor of Science
for Safer Pets
At NanoVet, we harness groundbreaking science to create targeted treatments that help our animal companions live safer, healthier lives.
We develop therapies that are specific, easier to produce, more accessible, and designed with pet's comfort and well-being in mind.
Innovation Designed for Human Health in Pet Care
NanoVet is a spin-off of Nanogrow Biotech, founded with the sole purpose of delivering cutting-edge human treatments for pet care. By connecting Nanogrow's innovative drug-discovery with feedback from veterinarians, we ensure our therapies fit real lives with real needs.
Our Technology
Why SdAbs?
SAFE + SIMPLE + Successful
Single-domain Antibodies are the smallest and most stable known antibodies. Due to its size, they emerge as a solution with improved penetrability and bioavailability compared to traditional monoclonal antibodies. They also have significant cost advantages, as they require much simpler biological expression systems for their production, generating affordable therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
The simplicity and stability of SdAbs enable scalable, high-yield, cost-effective production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
The simplicity and stability of SdAbs enable scalable, high-yield, cost-effective production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
The simplicity and stability of SdAbs enable scalable, high-yield, cost-effective production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
The simplicity and stability of SdAbs enable scalable, high-yield, cost-effective production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
The simplicity and stability of SdAbs enable scalable, high-yield, cost-effective production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
The simplicity and stability of SdAbs enable scalable, high-yield, cost-effective production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
The simplicity and stability of SdAbs enable scalable, high-yield, cost-effective production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
The simplicity and stability of SdAbs enable scalable, high-yield, cost-effective production across various expression systems.
Why We’re Different
Our Unique Platform
Our key feature is a one-of-a-kind platform that allows us to generate and select the best candidate for each disease, combining natural and computational tooling, with the most accurate formulation.
Best Tailored Candidate
Highly Optimized
IA Application
Best Tailored Candidate
Highly Optimized
IA Application
Best Tailored Candidate
Highly Optimized
IA Application
Best Tailored Candidate
Highly Optimized
IA Application
Treatments
Biologics Targeted Disorders
Atopic Dermatitis
A common inflammatory skin condition triggered by allergens like pollen, dust, or some foods. It leads to itching, redness, and recurring skin infections, impacting the animal’s quality of life. We are working on different delivery approaches to reduce side effects.
Atopic Dermatitis
A common inflammatory skin condition triggered by allergens like pollen, dust, or some foods. It leads to itching, redness, and recurring skin infections, impacting the animal’s quality of life. We are working on different delivery approaches to reduce side effects.
Atopic Dermatitis
A common inflammatory skin condition triggered by allergens like pollen, dust, or some foods. It leads to itching, redness, and recurring skin infections, impacting the animal’s quality of life. We are working on different delivery approaches to reduce side effects.
Oncology
Cancer is one of the leading causes of death in adult pets. Our solutions in veterinary oncology aim at making it possible to treat tumors more precisely, improving outcomes while reducing side effects. We are currently focusing on Mast Cell Tumors and Melanoma.
Oncology
Cancer is one of the leading causes of death in adult pets. Our solutions in veterinary oncology aim at making it possible to treat tumors more precisely, improving outcomes while reducing side effects. We are currently focusing on Mast Cell Tumors and Melanoma.
Oncology
Cancer is one of the leading causes of death in adult pets. Our solutions in veterinary oncology aim at making it possible to treat tumors more precisely, improving outcomes while reducing side effects. We are currently focusing on Mast Cell Tumors and Melanoma.
Osteoarthritis
A progressive joint disease that causes chronic pain, stiffness, and reduced mobility, particularly in aging or large-breed pets. We are developing treatments focused on slowing, stopping, and reversing the disease progression.
Osteoarthritis
A progressive joint disease that causes chronic pain, stiffness, and reduced mobility, particularly in aging or large-breed pets. We are developing treatments focused on slowing, stopping, and reversing the disease progression.
Osteoarthritis
A progressive joint disease that causes chronic pain, stiffness, and reduced mobility, particularly in aging or large-breed pets. We are developing treatments focused on slowing, stopping, and reversing the disease progression.
Infectious Diseases
Diseases caused by viruses, bacteria, or parasites can spread rapidly among animals, sometimes with severe consequences. Early diagnosis and targeted treatments are essential to protect pet health and prevent outbreaks.
Infectious Diseases
Diseases caused by viruses, bacteria, or parasites can spread rapidly among animals, sometimes with severe consequences. Early diagnosis and targeted treatments are essential to protect pet health and prevent outbreaks.
Infectious Diseases
Diseases caused by viruses, bacteria, or parasites can spread rapidly among animals, sometimes with severe consequences. Early diagnosis and targeted treatments are essential to protect pet health and prevent outbreaks.
Our Progress
Innovative Solutions
Atopic Dermatitis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Atopic Dermatitis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Melanoma
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Melanoma
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Mast Cell Tumors
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Mast Cell Tumors
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Ostheoarthritis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Ostheoarthritis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Canine Parvovirus
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Canine Parvovirus
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Ostheoarthritis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Ostheoarthritis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Atopic Dermatitis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Melanoma
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Mast Cell Tumors
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Ostheoarthritis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Canine Parvovirus
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Ostheoarthritis
Phase
Strategic Development
Selection
In vitro assays
Animal Models
Who Support Us
Latest Updates
Stay Informed and Updated
Contact
Partner with Us
Contact us to explore how we can collaborate to drive progress and achieve impactful results together.